MYGN
MYRIAD GENETICS INC
$4.54
+3.42%
$414.6M
No data for this timeframe.
Vol
Market Cap$414.6M
Cap SizeSmall Cap
Analyst ConsensusSell (13%)
Inst. Holders8 funds
Inst. Value$102.6M
Inst. Activity3 buys / 0 sells
Insider Activity5B / 1S
Insider Net $$655.4K
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. DE·CIK 0000899923·Prev Close $4.39
Recent Activity
Jun 8, 2026
Insider
Kumar Rashmi sold 15,000 shares
Director @ $4.46 ($66.8K)
Jun 4, 2026
Insider
Dreismann Heinrich sold 59,701 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Reitan Colleen F sold 59,701 shares
Director @ $0.00 ($0.00)
Jun 2, 2026
other
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
Myriad Genetics announces the appointment of Raj Jampa as chief technology officer (CTO).
May 27, 2026
Press
Myriad Genetics announced it will present data at ASCO 2026 showing its Precise MRD test achieved 97% baseline detection
Impact 4/10
Mar 17, 2026
Press
Myriad Genetics announced FDA approval of its MyChoice® CDx Test as the companion diagnostic for GSK's Zejula (niraparib
Impact 8/10
Feb 28, 2026
SEC
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased their positions in Myr
INST-CLUSTER — Impact 6/10
Feb 24, 2026
SEC
Myriad Genetics filed an S-3 shelf registration to potentially raise up to $200 million through future offerings of comm
S-3 — Impact 3/10
Price Targets
$6.25
+37.7% upside
Strong Buy
Current $4.54
Low $4.00
Median $5.75
High $10.00
8 analysts
$4.00
$10.00
Analyst Ratings
0Strong Buy
2Buy
9Hold
2Sell
3Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | TD Cowen | MAINTAIN | Hold → Hold |
| May 6, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| Feb 24, 2026 | UBS | MAINTAIN | Neutral → Neutral |
| Feb 24, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 ▼ -520.5% | $-0.12 — $0.03 | -216% YoY | 9 |
| Next Q | $0.07 ▲ +77.2% | $0.00 — $0.10 | 0% YoY | 9 |
| Current FY | $0.05 ▲ +1.5% | $-0.06 — $0.09 | -20% YoY | 9 |
| Next FY | $0.15 ▼ -3.1% | $0.04 — $0.33 | 216% YoY | 9 |
Latest Reports
NEUTRAL
Press
4/10
Myriad Genetics announced it will present data at ASCO 2026 showing its Precise MRD test achieved 97% baseline detection
May 27, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased their positions in Myr
Feb 28, 2026
NEUTRAL
S-3
3/10
Myriad Genetics filed an S-3 shelf registration to potentially raise up to $200 million through future offerings of comm
Feb 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $50.6M | — |
| MORGAN STANLEY | $22.2M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $10.8M | ADD |
| TWO SIGMA INVESTMENTS, LP | $5.6M | ADD |
| BANK OF AMERICA CORP | $5.3M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Kumar Rashmi | SELL | $66.8K |
| Jun 4, 2026 | Dreismann Heinrich | A | $0.00 |
| Jun 4, 2026 | Reitan Colleen | A | $0.00 |
| Jun 4, 2026 | Bisaro Paul | A | $0.00 |
| Jun 4, 2026 | Kumar Rashmi | A | $0.00 |
8 institutional holders with $102.6M total value (16,676,466 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 8,225,371 | $50.6M | 49.3% | — |
| 2 | MORGAN STANLEY | 3,607,789 | $22.2M | 21.6% | DOUBLED +182.1% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,753,711 | $10.8M | 10.5% | ADD +25.7% |
| 4 | TWO SIGMA INVESTMENTS, LP | 915,171 | $5.6M | 5.5% | ADD +25.6% |
| 5 | BANK OF AMERICA CORP /DE/ | 867,071 | $5.3M | 5.2% | ADD +77.5% |
| 6 | FMR LLC | 490,945 | $3.0M | 2.9% | DOUBLED +102.0% |
| 7 | WELLS FARGO & COMPANY/MN | 437,034 | $2.7M | 2.6% | ADD +79.5% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 379,374 | $2.3M | 2.3% | DOUBLED +1650.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 728,674 | 915,171 | +25.6% | $5.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 488,503 | 867,071 | +77.5% | $5.3M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 21,674 | 379,374 | +1650.4% | $2.3M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,336,030 | 1,678,900 | +25.7% | $12.1M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 544,454 | 728,674 | +33.8% | $5.3M | 2025-Q3 |
| UBS Group AG | TRIM | 796,994 | 492,646 | -38.2% | $3.6M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 448,374 | 21,674 | -95.2% | $156.7K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 1,614,582 | 4,554,080 | +182.1% | $24.2M | 2025-Q2 |
| UBS Group AG | ADD | 548,498 | 796,994 | +45.3% | $4.2M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 14,500 | 544,454 | +3654.9% | $2.9M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 249,774 | 448,374 | +79.5% | $2.4M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 238,810 | 428,761 | +79.5% | $2.3M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 2,631,156 | 416,547 | -84.2% | $2.2M | 2025-Q2 |
| FMR LLC | DOUBLED | 172,651 | 348,713 | +102.0% | $1.9M | 2025-Q2 |
| MORGAN STANLEY | ADD | 1,285,117 | 1,614,582 | +25.6% | $14.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 801,441 | 568,731 | -29.0% | $5.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 684,874 | 249,774 | -63.5% | $2.2M | 2025-Q1 |
| FMR LLC | ADD | 104,893 | 172,651 | +64.6% | $1.5M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 14,500 | — | $128.6K | 2025-Q1 |
| MORGAN STANLEY | ADD | 880,987 | 1,285,117 | +45.9% | $17.6M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 118,461 | 801,441 | +576.5% | $11.0M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 365,374 | 684,874 | +87.4% | $9.4M | 2024-Q4 |
| UBS Group AG | DOUBLED | 203,959 | 477,572 | +134.2% | $6.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 126,468 | 214,127 | +69.3% | $2.9M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,083,302 | — | $29.7M | 2024-Q3 |
17 unique insiders with 6 transactions. Net insider value: $655.4K ($722.2K bought, $66.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Kumar Rashmi | Director | SELL | 15,000 | $4.46 | $66.8K |
| Jun 4, 2026 | Dreismann Heinrich | Director | A | 59,701 | $0.00 | $0.00 |
| Jun 4, 2026 | Reitan Colleen F | Director | A | 59,701 | $0.00 | $0.00 |
| Jun 4, 2026 | Bisaro Paul | Director | A | 59,701 | $0.00 | $0.00 |
| Jun 4, 2026 | Kumar Rashmi | Director | A | 59,701 | $0.00 | $0.00 |
| Jun 4, 2026 | Skovronsky Daniel | Director | A | 59,701 | $0.00 | $0.00 |
| Jun 4, 2026 | Phanstiel S. Louise | Director | A | 59,701 | $0.00 | $0.00 |
| Jun 4, 2026 | Newcomer Lee Nisley | Director | A | 59,701 | $0.00 | $0.00 |
| Jun 4, 2026 | Davis Mark Steven | Director | A | 59,701 | $0.00 | $0.00 |
| Jun 1, 2026 | Jampa Raj | Chief Technology Officer | A | 251,889 | $0.00 | $0.00 |
| May 14, 2026 | Bisaro Paul | Director | BUY | 7,500 | $3.69 | $27.6K |
| May 1, 2026 | Donnelly Brian J | Chief Commerical Officer | F | 55,975 | $4.80 | $268.7K |
| Apr 14, 2026 | Verratti Mark | Chief Operating Officer | F | 1,069 | $4.91 | $5.2K |
| Apr 14, 2026 | Muzzey Dale | Chief Scientific Officer | F | 946 | $4.91 | $4.6K |
| Mar 22, 2026 | Muzzey Dale | Chief Scientific Officer | F | 2,019 | $4.58 | $9.2K |
| Mar 22, 2026 | Verratti Mark | Chief Operating Officer | F | 2,055 | $4.58 | $9.4K |
| Mar 22, 2026 | Wheeler Benjamin Richard | Chief Financial Officer | F | 549 | $4.58 | $2.5K |
| Mar 15, 2026 | Verratti Mark | Chief Operating Officer | F | 5,611 | $4.66 | $26.1K |
| Mar 15, 2026 | Haas Kevin Richard | Chief Technology Officer | F | 3,355 | $4.66 | $15.6K |
| Mar 15, 2026 | Wheeler Benjamin Richard | Chief Financial Officer | F | 877 | $4.66 | $4.1K |
| Mar 15, 2026 | Muzzey Dale | Chief Scientific Officer | F | 4,783 | $4.66 | $22.3K |
| Mar 14, 2026 | Solaiman Shereen | Chief People Officer | F | 5,784 | $4.66 | $27.0K |
| Mar 14, 2026 | Haas Kevin Richard | Chief Technology Officer | F | 4,161 | $4.66 | $19.4K |
| Mar 14, 2026 | Verratti Mark | Chief Operating Officer | F | 5,418 | $4.66 | $25.2K |
| Mar 14, 2026 | Wheeler Benjamin Richard | Chief Financial Officer | F | 1,097 | $4.66 | $5.1K |
| Mar 14, 2026 | Muzzey Dale | Chief Scientific Officer | F | 8,288 | $4.66 | $38.6K |
| Mar 14, 2026 | Raha Samraat S. | President and CEO | F | 10,816 | $4.66 | $50.4K |
| Mar 13, 2026 | Raha Samraat S. | President and CEO | F | 36,304 | $4.66 | $169.2K |
| Mar 13, 2026 | Solaiman Shereen | Chief People Officer | F | 8,899 | $4.66 | $41.5K |
| Mar 13, 2026 | Verratti Mark | Chief Operating Officer | F | 9,164 | $4.66 | $42.7K |
| Mar 13, 2026 | Fox Jennifer Lynne | Chief Legal Officer | F | 5,995 | $4.66 | $27.9K |
| Mar 13, 2026 | Haas Kevin Richard | Chief Technology Officer | F | 6,412 | $4.66 | $29.9K |
| Mar 13, 2026 | Wheeler Benjamin Richard | Chief Financial Officer | F | 586 | $4.66 | $2.7K |
| Mar 13, 2026 | Muzzey Dale | Chief Scientific Officer | F | 12,779 | $4.66 | $59.6K |
| Mar 12, 2026 | Donnelly Brian J | Chief Commerical Officer | A | 226,804 | $0.00 | $0.00 |
| Mar 12, 2026 | Solaiman Shereen | Chief People Officer | A | 173,196 | $0.00 | $0.00 |
| Mar 12, 2026 | Verratti Mark | Chief Operating Officer | A | 247,423 | $0.00 | $0.00 |
| Mar 12, 2026 | Wheeler Benjamin Richard | Chief Financial Officer | A | 206,186 | $0.00 | $0.00 |
| Mar 12, 2026 | Muzzey Dale | Chief Scientific Officer | A | 173,196 | $0.00 | $0.00 |
| Mar 12, 2026 | Fox Jennifer Lynne | Chief Legal Officer | A | 195,876 | $0.00 | $0.00 |
| Mar 12, 2026 | Raha Samraat S. | President and CEO | A | 618,557 | $0.00 | $0.00 |
| Mar 9, 2026 | Raha Samraat S. | President and CEO | BUY | 40,000 | $5.00 | $199.8K |
| Mar 1, 2026 | Solaiman Shereen | Chief People Officer | F | 1,675 | $4.61 | $7.7K |
| Feb 27, 2026 | Phanstiel S. Louise | Director | BUY | 48,000 | $4.66 | $223.7K |
| Feb 26, 2026 | Phanstiel S. Louise | Director | BUY | 50,407 | $4.80 | $242.1K |
| Feb 25, 2026 | Phanstiel S. Louise | Director | BUY | 6,100 | $4.74 | $28.9K |
| Feb 2, 2026 | Muzzey Dale | Chief Scientific Officer | A | 23,697 | $0.00 | $0.00 |
| Feb 2, 2026 | Wheeler Benjamin Richard | Chief Financial Officer | A | 4,994 | $0.00 | $0.00 |
| Feb 2, 2026 | Haas Kevin Richard | Chief Technology Officer | A | 23,697 | $0.00 | $0.00 |
| Feb 2, 2026 | Verratti Mark | Chief Operating Officer | A | 32,810 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.5/10.
Current analyst consensus: Strong Sell (13% buy). Based on 16 analysts: 0 strong buy, 2 buy, 9 hold, 2 sell, 3 strong sell.
Analyst Price Targets
$6.25 mean target
+37.7% upside
Strong Buy (3.00)
$4.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $4.54 |
| Target Low | $4.00 |
| Target Mean | $6.25 |
| Target Median | $5.75 |
| Target High | $10.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.12 | $0.03 | -215.6% | -520.5% | 1↑ 6↓ | $0.2B | -3.3% | 9 |
| Next Q 2026-09-30 |
$0.07 | $0.00 | $0.10 | 0.0% | +77.2% | 7↑ 0↓ | $0.2B | 9.3% | 9 |
| Current FY 2026-12-31 |
$0.05 | $-0.06 | $0.09 | -20.4% | +1.5% | 4↑ 3↓ | $0.9B | 4.7% | 9 |
| Next FY 2027-12-31 |
$0.15 | $0.04 | $0.33 | 216.3% | -3.1% | 3↑ 6↓ | $0.9B | 6.1% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.058 | |
| 7d ago | $-0.060 | +0.002 |
| 30d ago | $0.014 | -0.072 |
| 60d ago | $0.014 | -0.072 |
| 90d ago | $0.016 | -0.074 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | TD Cowen | MAINTAIN | Hold | Hold |
| May 6, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 24, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Feb 24, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 2 | 9 | 2 | 3 | 13% | |
| May 1, 2026 | 0 | 2 | 9 | 3 | 3 | 12% | |
| Apr 1, 2026 | 0 | 3 | 9 | 3 | 3 | 17% | |
| Mar 1, 2026 | 0 | 3 | 9 | 3 | 3 | 17% | |
| Feb 1, 2026 | 0 | 3 | 9 | 3 | 3 | 17% | |
| Jan 1, 2026 | 0 | 3 | 9 | 3 | 3 | 17% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
Myriad Genetics announces the appointment of Raj Jampa as chief technology officer (CTO).
May 27, 2026
fda
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
May 26, 2026
other
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence
May 15, 2026
contract
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Myriad Genetics joins forces with Nobody Wants This actress Jackie Tohn
May 7, 2026
other
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics will participate in The BofA Securities 2026 Health Care Conference and Goldman Sachs 47th Annual Global Healthcare Conference.
May 7, 2026
short_volume
Short Volume: MYGN — 59.2% short (0.8M / 1.4M)
Short: 802,244 | Exempt: 51,388 | TRF Vol: 1,354,666 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings_calendar
MYGN Q1 2026 Earnings After Market Close — 2026-05-05
May 4, 2026
earnings_calendar
MYGN Q1 2026 Earnings After Market Close — 2026-05-04
Apr 30, 2026
other
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn’t designed with them in mind.
Apr 30, 2026
earnings_calendar
MYGN Q1 2026 Earnings After Market Close — 2026-04-30
Apr 16, 2026
routine
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
Myriad Genetics will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting.
Apr 14, 2026
other
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
<p>SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Vys0za29ulXYBkLr8x35PvqlB9txOArPF0nDZ-PSNK
Apr 9, 2026
routine
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
Myriad will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting April 10-13, including two oral presentations and two posters.
Mar 17, 2026
fda
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian c
Mar 2, 2026
other
Myriad Commercially Launches Precise MRD with Select Community Oncologists
Myriad Genetics announces the launch of the Precise MRD test with a select number of oncology practices for patients with breast cancer.